We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO NAMED AS A 2011 FIERCE 15 BIOTECH COMPANY
Boston, MA – September 6, 2011 – TESARO, Inc., an oncology-focused biopharmaceutical company, announced that it has been named by FierceBiotech today as one of 2011's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.
View HTML
Toggle Summary TESARO ANNOUNCES $101 MILLION SERIES B FINANCING FOR ADVANCEMENT EXPANSION OF ONCOLOGY PRODUCT PORTFOLIO
- New Capital Funds: Development of Rolapitant through Phase 3 Trials and Potential Regulatory Submissions; Initial Clinical Trial for ALK Inhibitor Program; and Oncology Product Pipeline Expansion – Boston, MA – June 21, 2011 – TESARO, Inc., an oncology-focused biopharmaceutical
View HTML
Toggle Summary EXCLUSIVE LICENSE AGREEMENT WITH AMGEN TO ACQUIRE RIGHTS TO ANAPLASTIC LYMPHOMA KINASE (ALK) PROGRAM
TESARO will be responsible for worldwide development and commercialization Amgen's oral, small molecule ALK inhibitors are highly potent and selective, and possess desirable pharmaceutical properties Recent clinical proof-of-concept has been demonstrated for ALK inhibition in patients with ALK
View HTML
Toggle Summary TESARO AND OPKO HEALTH SIGN EXCLUSIVE LICENSE AGREEMENT FOR
Rolapitant is a Phase III-ready neurokinin-1 (NK-1) receptor antagonist in development for chemotherapy induced nausea and vomiting (CINV) TESARO will be responsible for worldwide development and commercialization Boston, MA and Miami, FL – December 14, 2010 – TESARO, Inc.
View HTML
Toggle Summary TESARO, INC. SECURES $60 MILLION IN START-UP FUNDING
Former MGI PHARMA Executives Found New Oncology-Focused Biopharma Company Initial Financing Provided by New Enterprise Associates (NEA) and Management Boston, MA – May 26, 2010 – TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $60 million
View HTML